key: cord-0819708-3d7w79ik
authors: Loke, Yue-Hin; Berul, Charles I.; Harahsheh, Ashraf S.
title: Multisystem Inflammatory Syndrome in Children: Is There a Linkage to Kawasaki Disease?
date: 2020-07-20
journal: Trends Cardiovasc Med
DOI: 10.1016/j.tcm.2020.07.004
sha: b4d8723331a6c7cbe4cc79251639214c2556902a
doc_id: 819708
cord_uid: 3d7w79ik

Since 1967, researches have hunted for an etiology for Kawasaki Disease (KD). Meanwhile, the 2019 Coronavirus Disease (COVID-19) pandemic has produced a strange new illness termed multisystem inflammatory syndrome in children (MIS-C) and raised hopes that a cause for KD may be identified. This current review paper discusses KD and its potential connection to pediatric COVID-19 and MIS-C illness.

The 2019 Coronavirus Disease (COVID-19) pandemic will likely be looked back upon as a testament to the rapid and voracious nature of evidence-based medicine in the 21 st century. For comparison, Kawasaki Disease (KD) is one of the most recognized pediatric inflammatory syndromes and took 6 years to be identified and reported by Dr. Tomisaku Kawasaki (1) .

Meanwhile, the COVID-19 pandemic has generated more than 19,000 publications of case reports, molecular studies, and clinical trials in less than 3 months' time.

Most have focused on COVID-19 in adults, as early data suggested that children were spared from severe disease (2) . However, since May 2020, multiple American and European institutions have brought attention to an enigmatic phenomenon known as multisystem inflammatory syndrome in children (MIS-C) with seeming connections and/or overlapping phenotype to KD (3) (4) (5) . This current review paper will discuss about KD and its potential connection to pediatric COVID-19 and MIS-C.

In 1967, Dr. Kawasaki published his detailed case series of 50 children that developed a condition he termed as -acute febrile mucocutaneous lymph node syndrome‖ (1) . The long term sequel of KD was not recognized until the 1970s, when surveys demonstrated a significant number of fatal cases secondary to coronary artery (CA) aneurysm (CAA) formation, with subsequent thrombosis and stenosis (6) .

Nowadays, KD is recognized as the leading cause of acquired CA disease in the pediatric population (7) . Standards of care were established in 1984, following the introduction of highdose intravenous immunoglobulin (IVIG) to reduce the prevalence of CA abnormalities (8) .

Since 2004, the American Heart Association (AHA) has published guidelines describing the management, treatment and long-term management of KD (7) . To date, over 300,000 children have been diagnosed and treated for KD (9) . However, despite emerging treatment options, the precise etiology of KD has remained elusive. KD remains a clinical diagnosis -all diagnostic findings are non-specific.

The most concerning complication of KD is CAAs that can be detected within 2 weeks during the convalescent stage of KD (10) . These abnormalities are typically identified by echocardiography. CAAs can be seen in 25% of untreated KD patients, and is reduced to 4% after the introduction of IVIG (7) . Current standard of care involves administering IVIG, along with high-dose oral aspirin, within 10 days (ideally 7 days) from onset of fever (7, 11) .

The pathology of CA abnormalities involves three phases (12) -#1) necrotizing arteritis in the acute phase, with neutrophils destroying the wall (tunica media to tunica adventitia) leading to aneurysmal formation; #2) subacute/chronic vasculitis involving T cell lymphocytes, plasma B cells and macrophages infiltrating the vessel wall; and #3) luminal myofibroblastic proliferation, involving myofibroblasts and matrix deposition over months and years that contributes to arterial stenosis. Thus, untreated KD patients with severe CAAs (i.e. large/giant aneurysms) typically do not have any cardiac symptoms in the acute phase, and may present with late manifestations of myocardial ischemia and/or sudden cardiac death secondary to severe CA flow disturbance and/or thrombosis (12) . Some of these patients are missed in the acute phase and are not diagnosed until the therapeutic window has passed, presenting with findings of severe CAAs.

Myocarditis can also occur in the acute phase of KD. Myocardial edema has been found in KD patients before CAA develop (13) . Rarely, true myocardial cell necrosis or permanent cellular loss can develop (14) . Oftentimes there is transient left ventricular (LV) dysfunction and ventricular ectopy (15) . In a small subset of KD patients, this will manifest as cardiovascular shock and hypotension requiring the use of intravascular volume boluses and vasoactive medications, KD shock syndrome (16) .

KD patients have characteristic serum lab findings of inflammation, albeit non-specific to other inflammatory disease (17) . Patients in acute phase of KD typically have leukocytosis with a predominance of neutrophils. Elevation of acute-phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) is always present and considered a key criterion particularly in cases of -incomplete‖ KD (7) . Thrombocytosis can be impressive and occur with peaks as high as 700 X10 3 /mL. Sterile pyuria is also common. N-terminal pro hormone B-type natriuretic peptide (NT-proBNP) is commonly elevated in KD patients (7) and is useful in diagnosis with a pooled sensitivity of 80 -89% and positive likelihood ratio of 3.2 (18, 19) . NT-proBNP may also potentially serve as a prognostic marker for IVIG resistance (19) .

The etiology, immunology and pathophysiology of KD are still not fully understood, although elements of the immune system clearly play a role (20, 21) . There are several proposed components, best summarized by Marrani et al (22) -#1) Response to a pathogen: KD is self-limited with low recurrence rate (23) , in addition to having seasonal variation in North America (24) . Additionally, RNA-containing intracytoplasmic inclusion bodies (25) and IgA antibodies (26) can also be found in the bronchial epithelium of KD patients. These studies suggest a viral pathogen activating the immune response via molecular mimicry (22) , and subsequent immunity against re-exposure. However, genetic profile has also identified that patients with acute KD have clear differences from other patients with viral disease (27) .

#2) T-cell driven autoimmune process: Anti-endothelial antibodies can be found in KD patients (28) , resembling other forms of vasculitis such as lupus or anti-phospholipid syndrome.

KD patients after IVIG appear to have increased regulatory T cells that affect immunomodulation (21) . However, few studies show association of KD patients with other forms of autoimmune disease.

#3) Aberrant activation of proinflammatory cytokines: During the acute phase, KD patients demonstrate massive release of interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF) (29) . IL-1 in particular has been implicated in CAA formation, leading to current trials investigating the use of IL-1 antagonists (Anakinra) to treat IVIG resistant CAAs (30) . However, autoimmune diseases involving cytokines are usually associated with single gene defects, whereas the KD profile suggests more polygenic influence (31) .

Ultimately, KD can be recognized as a complex inflammatory syndrome that occasionally affects the CAs of patients with genetic predisposition and a trigger. (Figure 1) Children of Asian and Pacific Islander descent are at highest riskin Japan, the annual incidence is ~ 260 per 100,000. In the United States (US), the overall incidence is ~ 25 per 100,000, highest amongst Asian Americans (similar to Japan) (32) . Despite decades of research and hundreds of suggested pathogens, ranging from superantigens to shampoo rugs (33, 34) , no clear-cut antigen has been definitely linked to KD. The rise of COVID-19 and MIS-C has now further challenged our understanding of KD.

Although children of all ages are susceptible to COVID-19, the impact and clinical manifestations have been less severe compared to the adult population. As of June 5th 2020, the US had 66,376 cases of COVID-19 in children <18 years old. The hospitalized rate is low with an estimated rate of 5.7%; the mortality rate is even lower in the US (35) . Proposed mechanisms include a stronger innate immune response compared to adults, and higher angiotensin converting enzyme (ACE)-2 expression which reduces the presence of angiotensin-2, known to correlate with COVID-19 viral load and clinical course (36,37).

In a cross-sectional study of North American pediatric intensive care units (PICUs), between March and April 2020, 48 children were admitted to 14 PICUs in the US (38). 73% presented with respiratory symptoms, and 38% required invasive ventilation. At our institution, which covers the District of Columbia (DC) metropolitan region (DC, Maryland, and Virginia), we have observed a steady increase of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) circulation in the 6 weeks since March 15, 2020 (39) . In our cohort, there was an association between other underlying comorbidities and hospitalization.

The -stay-at-home‖ self-quarantine orders, a necessity for controlling the COVID-19 pandemic, initially raised concern amongst pediatric cardiologists that the reduced contact with health care providers and over-emphasis of COVID-19 by Bayesian thinking would potentially lead to under recognition of KD (11) . A concerning surge in presence of CAAs was somewhat anticipated, although there was also speculation that social distancing would reduce exposure of plausible trigger agents for KD.

Thus, it was of great surprise to observe reports of pediatric patients treated for both COVID-19 and KD-like illness ( Figure 2 ) (40). The first case report was published in early April 2020 (41), but the first major call to attention was on April 26, 2020 when National Health Service in the United Kingdom (NHS UK) issued an alert to highlight a rise in cases of critically ill children with overlapping features of toxic shock syndrome, atypical KD and severe COVID-

Organization (WHO) (43-45). Case definitions from all three institutions are listed in Table 1 , but none is neither specific nor evidence based. There have been multiple descriptions and names, including Pediatric Multisystem Inflammatory Syndrome (PMIS) and MIS-C. For consistency we will use the CDC's definition -MIS-C‖.

To date, the clinical data related to MIS-C are mainly collected from COVID-19 epicenters in Europe and the US. Multiple case series have been published in eastern United States, Italy, UK and France (3, 4, (46) (47) (48) (49) (50) (51) (52) . The respective findings from several case series (with the largest representation for each region; combined for the US) are summarized in Table 2 and The overall MIS-C presentation appears to overlap KD with noticeable differences. A significant portion of patients had findings consistent with KD including rash, conjunctivitis, lymphadenopathy, extremity edema and fissured lips. 56% had evidence of decreased LV function by echocardiography. Cardiac magnetic resonance imaging in several of these patients demonstrated increased signal intensity on T1 and T2-weighted imaging, consistent with diffuse myocardial edema, with no enhancement on late gadolinium imaging to suggest fibrosis (52) .

Interestingly, only 15% had documented CA dilation, although the interpretation of CAA is affected by variations in image interpretation (i.e. absolute measurement vs. use of pediatric normative standards) and timing of echocardiography (i.e. whether echocardiography was performed before, during, or after immune modulation therapy). Laboratory findings include elevated troponin, NT-proBNP, inflammatory markers, as well as lymphopenia and thrombocytopenia (Table 3) .

Proponents of a connection between MIS-C and KD would argue that both conditions have a common trigger that provokes a cascade reaction in genetically susceptible children leading to the phenotype described above. (Figure 1) Opponents would argue that MIS-C children present with (1) older age of presentation,

(2) more profound form of inflammation than that of KD or KD shock syndrome, (3) more gastrointestinal manifestation, (4) different laboratory findings including lymphopenia, thrombocytopenia, elevated troponin, elevated NT-proBNP, elevated D-Dimer, and elevated ferritin, and (5) and have higher propensity towards LV dysfunction and shock compared to KD patients. (Table 4 ). They would also highlight how MIS-C seem to have less propensity towards children of Asian and Pacific Islander descent (49, 54) . The clinical patterns resemble that of toxic shock syndrome, typically the result of massive cytokine production, leading to capillary leak and subsequent hypotension (55) . 

The massive activation of pro-inflammatory cytokines in MIS-C patients overlaps laboratory findings in both KD and the -cytokine storm‖ observed in adult patients with COVID-19 (62, 63) . Cytokine storm is observed in many viral infections and toxic shock syndrome (55, 63) ; in the case of SARS-CoV-2, there is an associated increase in proinflammatory cytokines as well as macrophage activation (64) . Significant predictors of mortality in COVID-19 adult patients have included elevated serum ferritin and IL-6 (62). The cytokine storm pattern in MIS-C has also implicated macrophage activating syndrome (MAS) (47), which is seen in KD and autoimmune diseases such as systemic lupus erythematosus (65) . This has informed the use of steroids to treat some MIS-C patients (47). However, while these patients met ferritin criteria for MAS, the degree of elevation is considerably lower compared to historical cohorts (median 9,094 ng/mL, IQR of 2,000-19,767 ng/mL) (65) .

The role of coronavirus as a potential trigger for KD has been previously proposed with mixed results. Coronavirus has been noted in KD patients but not in exclusive fashion (i.e. concurrent viral illness) (66) . Specific strains of coronavirus have also been associated with KD in small case series (67) that could not be reproduced in other locations (68) . The viral genomics of coronavirus challenges the identification of any triggers for KD, as coronavirus is a positive sense RNA virus (69) and its genome is prone to mutation and genetic drift (59) . Still, the absence of preceding symptoms, the 3 -6 week lag between virus prevalence and MIS-C prevalence, and higher frequency of positive antibody results suggests that SARS-CoV-2 acts as a trigger (5) .

It is poignant and bittersweet to note that the quick recognition of MIS-C is only possible Nonetheless, the presentation of CAAs in a small but significant portion of MIS-C patients warrants caution and continued surveillance. Cardiologists will continue to have a role in providing accurate assessment of CAs and myocardial function to guide management (7) . Longterm studies are essential for MIS-C and COVID-19 patients, in the form of registry data and genomics (59, (73) (74) (75) . These studies will help define the clinical course, epidemiology, mechanism of MIS-Cand potentially even KD itself. The COVID-19 pandemic may serve as both challenge and opportunity for us to understand an inflammatory syndrome that -God Only pending. Copyright (2020). We will request permission from Elsevier 

Neutrophilia, elevated CRP and lymphopaenia

Including, but not limited to, one or more of the following: an elevated CRP, ESR, fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin

Elevated markers of inflammation such as ESR, CRP, or procalcitonin.

Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice)

No alternative plausible diagnoses No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

May include children fulfilling full or partial criteria for KD.

Consider 

Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children

SARS-CoV-2 Infection in Children

Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet

Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department

Kawasaki Disease and SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children

A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

The treatment of Kawasaki syndrome with intravenous gamma globulin

Kawasaki disease: epidemiology and the lessons from it

Association of Initially Normal Coronary Arteries With Normal Findings on Follow-up Echocardiography in Patients With Kawasaki Disease

Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic

Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study

Histopathological characteristics of myocarditis in acute-phase Kawasaki disease: Myocarditis in Kawasaki disease

Biopsy-proven myocardial sequels in Kawasaki disease with giant coronary aneurysms

Changes in causes of sudden deaths by decade in patients with coronary arterial lesions due to Kawasaki disease

Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome

Evolution of Laboratory Values in Patients With Kawasaki Disease: Pediatr Infect Dis J

Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and metaanalysis

A Decade of NT-proBNP in Acute Kawasaki Disease, from Physiological Response to Clinical Relevance

Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease

Specificity of regulatory T cells that modulate vascular inflammation

How Should We Classify Kawasaki Disease? Front Immunol

Recurrent Kawasaki disease: USA and Japan: Recurrent KD: USA and Japan

Seasonality of Kawasaki Disease: A Global Perspective

RNA-Containing Cytoplasmic Inclusion Bodies in Ciliated Bronchial Epithelium Months to Years after Acute Kawasaki Disease

Oligoclonal IgA Response in the Vascular Wall in Acute Kawasaki Disease

Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease

The role of antiendothelial cell antibodies in Kawasaki disease -in vitro and in vivo studies

Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease

Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm

A genome-wide association study identifies three new risk loci for Kawasaki disease

Epidemiology of Kawasaki Disease in Asia, Europe, and the United States

KAWASAKI SYNDROME: ASSOCIATION WITH THE APPLICATION OF RUG SHAMPOO. The Lancet

Conjunctival changes in children with Kawasaki disease: cytopathologic characterization

Coronavirus Disease 2019 in Children -United States

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents

Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care

Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series

Childhood Inflammatory Disease Related to COVID-19

Pediatric COVID-associated Multi-system Inflammatory Syndrome (PMIS)

Toxic Shock Syndrome

Should Coronavirus Disease 2019-Associated Inflammatory Syndromes in Children Affect Social Reintegration? JAMA Pediatr. Accepted, DOI pending

Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy

disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall Hoboken NJ

Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. Pathogens

The D614G mutation in the SARS-CoV-2 spike protein reduces S1

An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19)

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat: EULAR/ACR CLASSIFICATION CRITERIA FOR MAS. Arthritis Rheumatol

Concurrent Respiratory Viruses and Kawasaki Disease

Association between a Novel Human Coronavirus and Kawasaki Disease

Lack of association between New Haven coronavirus and Kawasaki disease

Molecular immune pathogenesis and diagnosis of COVID-19

doctor who identified inflammatory disease in children, dies at 95. The Washington Post

Covid-19, Kawasaki disease, and Multisystem Inflammatory Syndrome in Children

Covid-19 and Kawasaki Disease: A Glimpse at the Past for a Predictable Future

Establishment of Kawasaki disease database based on metadata standard

Low Molecular Weight Heparin vs. Warfarin for Thromboprophylaxis in Children with Coronary Artery Aneurysms After Kawasaki Disease: A Pragmatic Registry Trial

Mediumterm complications associated with coronary artery aneurysms after Kawasaki Disease: A study from the International Kawasaki Disease Registry

NT-Pro-B-type Natriuretic Peptide in Infants and Children: Reference Values Based on Combined Data from Four Studies

Acknowledgment: The authors are grateful for Dr Angela J Doty and Lindsay Attaway for their editorial assistance.